Literature DB >> 30500079

An endogenous aryl hydrocarbon receptor ligand enhances de novo generation of regulatory T cells in humans.

Imen Zamali1,2, Raja Rekik1, Nadia Belhadj Hmida3, Ahlem Ben Hmid1,2, Ons Kammoun1, Mohamed-Ridha Barbouche2,3, Mélika Ben Ahmed1,2,3.   

Abstract

The aromatic hydrocarbons receptor (AhR) is a ligand-dependent transcription factor that plays a role in mediating toxicity to xenobiotics. Its key role in immune regulation has been recently demonstrated. Recent data pointed to the efficacy of ITE (2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester), a nontoxic ligand of AhR, in experimental models of inflammatory diseases. Such effect was mainly through the expansion of regulatory T cells (Tregs). Similarly, TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin), a toxic ligand of AhR, has been shown to exert comparable effects on Tregs in mice. Herein, we showed that ITE has no effects on natural Tregs. However, it supports the de novo generation of Tregs in humans while promoting their suppressive functions. Our data bring new elements supporting the use of ITE in human therapy of inflammatory diseases. ©2018 Society for Leukocyte Biology.

Entities:  

Keywords:  T lymphocytes; endogenous AhR ligand; immunotherapy

Mesh:

Substances:

Year:  2018        PMID: 30500079     DOI: 10.1002/JLB.2AB0518-205RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  2 in total

Review 1.  Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications.

Authors:  Leila Amini; Jenny Greig; Michael Schmueck-Henneresse; Hans-Dieter Volk; Séverine Bézie; Petra Reinke; Carole Guillonneau; Dimitrios L Wagner; Ignacio Anegon
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

Review 2.  Targeting AhR as a Novel Therapeutic Modality against Inflammatory Diseases.

Authors:  Alkeiver S Cannon; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Int J Mol Sci       Date:  2021-12-28       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.